



Imaging Biomarkers for Retinal Diseases: Prognostic Tools and Novel Clinical Trial Endpoints for Precision Medicine

Guest Editor:

Prof. Dr. Justis P. Ehlers

Tony and Leona Campana
Center for Excellence in Image-
Guided Surgery and Advanced
Imaging Research, Cole Eye
Institute, Cleveland Clinic, OH,
USA

Deadline for manuscript
submissions:

31 May 2024

Message from the Guest Editor

Advancements in imaging technology have transformed the field of retinal diseases through new insights in disease pathogenesis and prognosis. Advancements in image feature extraction and analysis technology, such as machine learning, has enabled the next-generation identification and quantification of imaging biomarkers for macular diseases across multiple imaging modalities. These biomarkers present unique opportunities to enhance personalized medicine in retinal disease management through improved patient education, progression risk prognostication, clinical trial enrichment, and even new potential end points. As new therapies emerge, the enhanced phenotyping of these biomarkers may provide important information regarding precision medicine and decision-making for treatment.

This Special Issue of the Journal for Personalized Medicine aims to highlight imaging biomarkers for retinal diseases across various modalities using advanced image analysis techniques. We look forward to receiving manuscripts related to new imaging biomarker discovery, image analysis techniques, and assessments of imaging biomarkers within clinical trial datasets.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer
Institute, Winston-Salem, NC
27103, USA

2. Division of Hematologic
Malignancies and Cellular
Therapy, Duke University,
Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q2 (*Medicine, General & Internal*) CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)